- Nanexa granted Novo Nordisk exclusive rights to use its PharmaShell atomic layer deposition coating across up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions.
- The agreement is worth up to $1.33 billion, with Nanexa eligible for an upfront payment of about $700 million plus development and regulatory milestone payments and low single-digit royalties on future product sales.
- The partnership targets injectable drugs administered monthly or quarterly, extending dosing intervals beyond current weekly GLP-1 regimens.
- Nanexa shares rose more than 150% at the Stockholm open before paring to a gain of about 114%, leaving the stock roughly 12% below its November 2015 all-time high.
- Nanexa reported full-year 2025 revenues of approximately $3.89 million, a 48.4% increase on the prior year, making the upfront payment a step-change in scale for the company.
Quotes
“With this agreement, Nanexa enters a new era of considerable financial strength, allowing us to significantly expand applications of our unique”
“provides a strong foundation for expanding PharmaShell into additional therapeutic areas and to selectively advance additional internal programs towards clinical proof of concept”